Search Results for: mirgaine day of action – Page 5

New Drug Offers Hope to Millions With Severe Migraines

The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a

Read More »

Move For Migraine

Move For Migraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working

Read More »

EMHA for Industry

For Industry. Cooperating in finding solutions for patients. WHAT CAN EMHA DO FOR THE INDUSTRY. Cooperating in finding solutions for patients. Working together is the only way to find effective and lasting solutions for migraine sufferers. By encouraging research, supporting projects and working to distribute reliable information, we can achieve a better quality of life

Read More »

Lilly Receives Positive CHMP Opinion for Emgality

INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least

Read More »

First monoclonal antibody therapy for prevention of migraine

First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity

Read More »

Intranasal ketamine for chronic migraine

Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: Research Subanesthetic ketamine infusion has been used for managing refractory headache in inpatient or outpatient infusion settings. Intranasal ketamine may be an alternative option for outpatient care. Methods A retrospective study was conducted at a single tertiary headache center to assess the clinical

Read More »

Mindfulness and Chronic Migraine

Mindfulness, pharmacological prophylaxis and Chronic Migraine MINDFULNESS AND PHARMACOLOGICAL PROPHYLAXIS AFTER WITHDRAWAL FROM MEDICATION OVERUSE IN PATIENTS WITH CHRONIC MIGRAINE: AN EFFECTIVENESS TRIAL WITH A ONE-YEAR FOLLOW-UP.Chronic Migraine (CM) is a disabling condition, worsened when associated with Medication Overuse (MO). Mindfulness is an emerging technique, effective in different pain conditions, but it has yet to

Read More »

The impact of headache in Europe

The impact of headache in Europe THE IMPACT OF HEADACHE IN EUROPE — EVIDENCE FROM THE EUROLIGHT STUDYEurolight was a cross-sectional questionnaire-based survey in 10 European countries. Sampling was population-based in six (Germany, Italy, Lithuania, Luxembourg, Netherlands, Spain) and from consecutive patients attending general practitioners (GPs) for any reason in three (Austria, France, UK). Additional

Read More »

Migraine in Europe

Poor medical care for people with migraine in Europe. EUROLIGHT STUDY—Migraine in Europe.Migraine is prevalent everywhere, and disabling. It is also neglected: consequently, it is underdiagnosed and undertreated. We analysed data from the Eurolight study on consultations and utilization of migraine-specific medications as indicators of adequacy of medical care in Europe. The study Migraine is

Read More »


We are an alliance The European Migraine and Headache Alliance is a non-profit patient association, which functions as an umbrella organisation for different patient groups across Europe. The Alliance was establi- shed in 2006 and since then we represent more than 30 patient groups across the continent. Also, we work closely with International Associates in Canada, US, Turkey, Argentina,

Read More »
Scroll to Top
Close this search box.